TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
← New search
Home›Stocks›RKDA
RKDA logo

RKDA

Arcadia Biosciences, Inc.

Next earnings Aug 12, 2026 · consensus $-0.57 EPS, $1.94M rev

Last earnings +0.9% on 2026-05-14

Avoid
$0.73
▲ +1.95%
$0.73▼ -82.79%
over 1Y
L $0.67H $5.48
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.9%
1W+8.6%
1M-27.4%
3M-45.8%
YTD-65.9%
1Y-82.8%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Avoid
Quality
C-
Valuation
Fair value
Filings
Flagged
Avoid
Conviction
Horizon
Long (>12mo)
Street · 7 analysts
Buy

Sub-$2M shell burning $4.7M/yr on $259K cash, with its oil-pivot reverse merger dead — a going-concern trap, not an investment.

Cash & equivalents $259K · FY2025

Arcadia is a $1.51M micro-cap husk whose entire forward thesis just evaporated. Management spent 2024–2025 dismantling the legacy wheat-trait business — selling the RS durum trait to Corteva ($4.0M) and the GoodWheat brand to Above Food ($3.7M) — then bet the company on an all-stock reverse merger with oil-and-gas partnership Roosevelt Resources that would have handed Roosevelt's limited partners 90% of the company. On December 24, 2025, Roosevelt terminated that Exchange Agreement. The 'Crude Petroleum & Natural Gas' SIC code is a fossil of a pivot that no longer exists; what remains is the Zola coconut-water business generating $4.86M of shrinking revenue (-3.7% YoY, and down from $7.42M in FY2022).

The balance sheet is the disqualifier. Cash fell 93.9% to just $259K while operating cash flow was -$4.74M for the year — the company burned roughly eighteen times its remaining cash and has no debt capacity story here, only equity. R&D has been cut to essentially nothing ($9K, -83%), confirming there is no product pipeline left to fund; this is a company in wind-down or desperate-recapitalization mode, not growth. Total assets collapsed 51.6% to $6.55M and stockholders' equity fell to $4.14M against a staggering -$281M accumulated deficit. Share count already rose 50.5% YoY to 2.06M, and the only realistic path to survival is further dilutive issuance or another merger of necessity — either of which transfers value away from today's holders.

Is RKDA a buy? The one-page verdict, explained →

The options angle

model · matches our verdict
Bear put spread (caution)~90d expiry
  • Long put 0.5 @ ~0.03 est
  • Short put 0.5 @ ~0.03 est
debit $0max +$0max $0

AVOID means we wouldn't engage at all — if expressing the short side anyway, only with capped risk.

Open in the calculator →

Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue$6.78M$7.42M$4.45M$5.04M$4.86M
Gross profit—————
Operating income-$35.5M-$14.0M-$6.10M-$3.65M-$2.50M
Net income-$14.7M-$15.4M-$14.0M-$7.04M-$2.34M
Diluted EPS-$27.56-$25.65-$11.29-$5.17-$1.71
Net margin-216.2%-207.3%-313.9%-139.5%-48.1%

10-year statements — income, cash flow, balance sheet & CSV export →

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$1.34M
EV / EBITDA—
EV / Sales0.3
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-146.3%
FCF yield-296.3%

Quality & risk

ROIC (est.)-47.7%
Free cash flow-$4.74M
Total debt$0.00
Net cash$259K
Altman Z-Score-59.48 distress
Piotroski F-Score3/8

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+50.5%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Recent disclosure tone has skewed negative — read the flagged items.
  1. 8-K Officer / director change2026-07-02

    Officer/director change plus shareholder-nomination notice and other events disclosed

  2. S-3 Shelf registration (potential raise)2026-06-26

    Filed shelf registration — capacity for future dilutive capital raises

  3. 8-K Material agreement2026-06-15

    New material agreement and unregistered share sale — dilutive private placement

  4. 8-K Earnings results2026-05-14

    Q1 2026: cash down to ~$0.3M, going-concern doubt persists despite smaller loss

  5. 10-Q Quarterly report2026-05-14

    Q1 2026: cash down to ~$0.3M, going-concern doubt persists despite smaller loss

  6. 10-K/A Restated periodic report2026-04-30

    Amended FY2025 10-K (Part III/technical) — no financial restatement

  7. 8-K Auditor change2026-04-03

    Changed independent registered accountant — auditor switch

  8. 8-K Earnings results2026-03-26

    FY2025: Roosevelt merger terminated; loss narrowed but cash critically low

  9. 10-K Annual report2026-03-26

    FY2025: Roosevelt merger terminated; loss narrowed but cash critically low

Recent filings

all on EDGAR ↗
8-KPeriod ending 2026-07-012026-07-02open ↗DFiling2026-06-26open ↗S-3Filing2026-06-26open ↗8-KPeriod ending 2026-06-112026-06-15open ↗SCHEDULE 13GFiling2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-14open ↗8-KPeriod ending 2026-05-142026-05-14open ↗10-K/APeriod ending 2025-12-312026-04-30open ↗8-KPeriod ending 2026-03-302026-04-03open ↗10-KPeriod ending 2025-12-312026-03-26open ↗8-KPeriod ending 2026-03-262026-03-26open ↗424B3Filing2026-02-11open ↗

Quality score

C-
ValueGrowthProfitHealthMom.
ValueA+
GrowthB-
ProfitabilityF
Financial healthB-
MomentumF
  • ✗Revenue growing year-over-year
  • ✗Profitable (positive net income)
  • ✗Net margin above 10%
  • ✗Return on equity above 15%
  • ✓Liabilities below 2× equity
0.6752-week5.48
Revenue
$4.86M
-3.7% YoY
Net margin
-48.1%
ROE
-56.5%
P/E
—

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$4.86M-3.7%
Net income-$2.34M+66.8%
Operating income-$2.50M+31.5%
Diluted EPS-$1.71+66.9%
Cash & equivalents$259K-93.9%
Total assets$6.55M-51.6%
Total liabilities$2.41M-67.0%
Stockholders' equity$4.14M-33.5%
Op.: -51.5%L/E: 0.58x

Frequently asked

Is Arcadia Biosciences, Inc. (RKDA) a buy?
RKDA currently carries a Avoid rating with 5/5 conviction, derived from its latest SEC filings. Sub-$2M shell burning $4.7M/yr on $259K cash, with its oil-pivot reverse merger dead — a going-concern trap, not an investment.
What is Arcadia Biosciences, Inc.'s quality score?
RKDA scores 53.11077683504301/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001469443, latest 10-Q filed 2026-05-14) · EODHD · Proprietary analysis · as of 7/4/2026, 10:36:53 AM.

›About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice

AI-generated analysis, produced by our proprietary engine from SEC filing data.

Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 6:36 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2025-02-03
Kawakami Mark
Chief Financial Officer
Buy700.00 @ $2.49$1.74K
2025-02-03
Schaefer Thomas J.
Chief Executive Officer
Buy700.00 @ $2.49$1.74K

Earnings history

beat/miss · move
2026-05-14—▼ -11.79%8-K ↗
2026-03-26—▼ -16.00%8-K ↗
2025-11-07Beat +212.6% est▼ -1.07%8-K ↗
2025-08-14Beat +102.5% est▼ -1.43%8-K ↗
2025-05-08Beat +290.1% est▲ +2.95%8-K ↗
2025-03-20Miss -229.4% est▼ -2.48%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Vs tracked universe

compare →

1195 tracked peers · median

TENK Score53 vs 67
Revenue growth-3.7% vs 7.5%
Net margin-48.1% vs 10.0%
Return on equity-56.5% vs 12.0%
P/E— vs 26.2